In the wake of Summit’s results, drugs like ivonescimab, which block cell signaling via proteins called PD-1 and VEGF, have become the “new shiny object” in cancer research, according to ...

Excellent safety observed across initial dose escalation with objective response at the lowest dose tested (1 mg/kg of AI-081)ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late ...

Key Takeaways Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence ...

Summary Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two ...

Innovent’s anti-VEGF drug held its own against Regeneron and Bayer’s blockbuster eye disease therapy Eylea in a phase 2 trial. The study saw 132 participants with neovascular age-related ...

Intravitreal anti-VEGF agents are linked to a slight increase in the risk for stroke in patients with age-related macular degeneration, but only for about 2 months after the last injection.

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field with a potential market that could be comparable to Pembrolizumab's market, which generated $29B in 2024. While ...

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio ...